Search

Author/Creator Xie, Ran

3. A multi-herb-combined remedy to overcome hyper-inflammatory response by reprogramming transcription factor profile and shaping monocyte subsets. (July 2021)

Authors:
De, Gejing; Chen, Apeng; Zhao, Qinghe; Xie, Ran; Wang, Chaoxi; Li, Meng; Zhao, Haiyu; Gu, Xinru; McCarl, Lauren H.; Zhang, Fangbo; Cai, Weiyan; Yang, Miyi; Lin, Peihui; Liu, Shaorong; Bian, Baolin
Journal:
Pharmacological research
Issue:
Volume 169(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study. Issue 6 (25th March 2022)

Authors:
Zhou, Shuang; Xie, Ran; Zhang, Xiaodan; He, Xu; Huang, Jie; Jungang, Yin; Liao, Man; Ding, Ying; Yang, Dandan; Liu, Ying; Zhang, Qian; Yang, Guoping; Liu, Fang; Guan, Shengjiang; He, Qing; Lou, Honggang; Gong, Fengyun; Meng, Xianmin; Xiang, Qian; Zhao, Xia
Journal:
Clinical and translational science
Issue:
Volume 15:Issue 6(2022)
Page Start:
1439
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. (4th December 2022)

Authors:
Taylor, Matthew H.; Leboulleux, Sophie; Panaseykin, Yury; Konda, Bhavana; de La Fouchardiere, Christelle; Hughes, Brett G. M.; Gianoukakis, Andrew G.; Park, Young Joo; Romanov, Ilia; Krzyzanowska, Monika K.; Garbinsky, Diana; Sherif, Bintu; Pan, Jie Janice; Binder, Terri A.; Sauter, Nicholas; Xie...
Journal:
Cancer medicine
Issue:
Volume 12:Number 4(2023)
Page Start:
4332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Issue 3 (March 2023)

Authors:
Choueiri, Toni K; Eto, Masatoshi; Motzer, Robert; De Giorgi, Ugo; Buchler, Tomas; Basappa, Naveen S; Méndez-Vidal, María José; Tjulandin, Sergei; Hoon Park, Se; Melichar, Bohuslav; Hutson, Thomas; Alemany, Carlos; McGregor, Bradley; Powles, Thomas; Grünwald, Viktor; Alekseev, Boris; Rha, Sun Youn...
Journal:
Lancet oncology
Issue:
Volume 24:Issue 3(2023)
Page Start:
228
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗